A Prospective Study to Evaluate the Intra-individual Reproducibility of Bone Scans for Quantitative Assessment in Patients with Metastatic Prostate Cancer

Overview

Journal BMC Med Imaging

Publisher Biomed Central

Specialty Radiology

Date 2018 May 6

PMID 29728144

Citations 1

Authors

Mariana Reza

Reza Kaboteh

May Sadik

Anders Bjartell

Per Wollmer

Elin Tragardh

Affiliations

Soon will be listed here.

Abstract

Background: The Bone Scan Index (BSI) is used to quantitatively assess the total tumour burden in bone scans of patients with metastatic prostate cancer. The clinical utility of BSI has recently been validated as a prognostic imaging biomarker. However, the clinical utility of the on-treatment change in BSI is dependent on the reproducibility of bone scans. The objective of this prospective study is to evaluate the intra-patient reproducibility of two bone scan procedures performed at a one-week interval.

Methods: We prospectively studied prostate cancer patients who were referred for bone scintigraphy at our centres according to clinical routine. All patients underwent two whole-body bone scans: one for clinical routine purposes and a second one as a repeated scan after approximately one week. BSI values were obtained for each bone scintigraph using EXINI bone software.

Results: A total of 20 patients were enrolled. There was no statistical difference between the BSI values of the first (median = 0.66, range 0-40.77) and second (median = 0.63, range 0-22.98) bone scans (p = 0.41). The median difference in BSI between the clinical routine and repeated scans was - 0.005 (range - 17.79 to 0). The 95% confidence interval for the median value was - 0.1 to 0. A separate analysis was performed for patients with BSI ≤ 10 (n = 17). Differences in BSI were smaller for patients with BSI ≤ 10 compared to the whole cohort (median - 0.1, range - 2.2-0, 95% confidence interval - 0.1 to 0).

Conclusions: The automated BSI demonstrated high intra-individual reproducibility for BSI ≤ 10 in the two repeated bone scans of patients with prostate cancer. The study supports the use of BSI as a quantitative parameter to evaluate the change in total tumour burden in bone scans.

Citing Articles

Skeleton Segmentation on Bone Scintigraphy for BSI Computation.

Yu P, Lai Y, Chen Y, Cheng D Diagnostics (Basel). 2023; 13(13).

PMID: 37443695 PMC: 10340357. DOI: 10.3390/diagnostics13132302.

References

Van den Wyngaert T, Strobel K, Kampen W, Kuwert T, van der Bruggen W, Mohan H . The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging. 2016; 43(9):1723-38. PMC: 4932135. DOI: 10.1007/s00259-016-3415-4. View

Anand A, Morris M, Kaboteh R, Reza M, Tragardh E, Matsunaga N . A Preanalytic Validation Study of Automated Bone Scan Index: Effect on Accuracy and Reproducibility Due to the Procedural Variabilities in Bone Scan Image Acquisition. J Nucl Med. 2016; 57(12):1865-1871. PMC: 6952052. DOI: 10.2967/jnumed.116.177030. View

Anand A, Morris M, Kaboteh R, Bath L, Sadik M, Gjertsson P . Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer. J Nucl Med. 2015; 57(1):41-5. PMC: 4975929. DOI: 10.2967/jnumed.115.160085. View

Reza M, Ohlsson M, Kaboteh R, Anand A, Franck-Lissbrant I, Damber J . Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone Acetate (Zytiga) in Clinical Practice. Eur Urol Focus. 2017; 2(5):540-546. DOI: 10.1016/j.euf.2016.02.013. View

Kaboteh R, Damber J, Gjertsson P, Hoglund P, Lomsky M, Ohlsson M . Bone Scan Index: a prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapy. EJNMMI Res. 2013; 3(1):9. PMC: 3570487. DOI: 10.1186/2191-219X-3-9. View

Suzman D, Boikos S, Carducci M . Bone-targeting agents in prostate cancer. Cancer Metastasis Rev. 2014; 33(2-3):619-28. PMC: 4087085. DOI: 10.1007/s10555-013-9480-2. View

Li D, Lv H, Hao X, Dong Y, Dai H, Song Y . Prognostic value of bone scan index as an imaging biomarker in metastatic prostate cancer: a meta-analysis. Oncotarget. 2017; 8(48):84449-84458. PMC: 5663610. DOI: 10.18632/oncotarget.19680. View

Mitsui Y, Shiina H, Yamamoto Y, Haramoto M, Arichi N, Yasumoto H . Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer. BJU Int. 2012; 110(11 Pt B):E628-34. DOI: 10.1111/j.1464-410X.2012.11355.x. View

Bombardieri E, Aktolun C, Baum R, Bishof-Delaloye A, Buscombe J, Chatal J . Bone scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2004; 30(12):BP99-106. DOI: 10.1007/s00259-003-1347-2. View

10.

Shintawati R, Achmad A, Higuchi T, Shimada H, Hirasawa H, Arisaka Y . Evaluation of bone scan index change over time on automated calculation in bone scintigraphy. Ann Nucl Med. 2015; 29(10):911-20. DOI: 10.1007/s12149-015-1021-3. View

11.

Heidenreich A, Bastian P, Bellmunt J, Bolla M, Joniau S, van der Kwast T . EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2013; 65(2):467-79. DOI: 10.1016/j.eururo.2013.11.002. View

12.

Sadik M, Suurkula M, Hoglund P, Jarund A, Edenbrandt L . Improved classifications of planar whole-body bone scans using a computer-assisted diagnosis system: a multicenter, multiple-reader, multiple-case study. J Nucl Med. 2009; 50(3):368-75. DOI: 10.2967/jnumed.108.058883. View

13.

Ulmert D, Kaboteh R, Fox J, Savage C, Evans M, Lilja H . A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol. 2012; 62(1):78-84. PMC: 3402084. DOI: 10.1016/j.eururo.2012.01.037. View

14.

Ulmert D, Solnes L, Thorek D . Contemporary approaches for imaging skeletal metastasis. Bone Res. 2015; 3:15024. PMC: 4502405. DOI: 10.1038/boneres.2015.24. View

15.

Kaboteh R, Gjertsson P, Leek H, Lomsky M, Ohlsson M, Sjostrand K . Progression of bone metastases in patients with prostate cancer - automated detection of new lesions and calculation of bone scan index. EJNMMI Res. 2013; 3(1):64. PMC: 3751570. DOI: 10.1186/2191-219X-3-64. View

16.

Dennis E, Jia X, Mezheritskiy I, Stephenson R, Schoder H, Fox J . Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol. 2012; 30(5):519-24. PMC: 3295554. DOI: 10.1200/JCO.2011.36.5791. View

17.

Wong K, Ma W, Wong C, Wong M, Tsang C, Tsu H . Impact of skeletal-related events on survival in patients with metastatic prostate cancer prescribed androgen deprivation therapy. Hong Kong Med J. 2015; 22(2):106-15. DOI: 10.12809/hkmj144449. View

18.

Macherey S, Monsef I, Jahn F, Jordan K, Yuen K, Heidenreich A . Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev. 2017; 12:CD006250. PMC: 6486306. DOI: 10.1002/14651858.CD006250.pub2. View

19.

Reza M, Jones R, Aspegren J, Massard C, Mattila L, Mustonen M . Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM-201 in the ARADES Multicentre Study. Eur Urol Focus. 2017; 2(5):547-552. DOI: 10.1016/j.euf.2016.01.005. View